The target audience for the professional campaign for Xifaxan 550 mg for hepatic encephalopathy (HE) is healthcare providers. Specialist audiences include gastroenterologists who treat liver disease and hepatologists.

In the United States, marketing of prescription pharmaceutical products such as Xifaxan 550 mg is regulated by the Food and Drug Administration (FDA) through the Office of Prescription Drug Promotion (OPDP). OPDP reviews promotional materials through its own surveillance programs of what is in market and through voluntary advance submissions from pharmaceutical companies.